LTR Pharma Logo

LTR Pharma

LTR Pharma is a Clinical Stage Biopharmaceutical Company

SPONTAN® (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction

About Erectile Dysfunction

Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.

Our Solution

SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects


LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years


worldwide expected cases by 2025


minute effectiveness


projected global market value 2024

Global Market Need

ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.


LTR Pharma Couple



The Australian | 30 November 2023

LTR Pharma has been featured in The Australian,  for our innovative breakthrough in men’s health – erectile dysfunction nasal spray, Spontan. In the article, non-exective director Dr. Julian Chick highlights the essence of Spontan, emphasising its simple proposition – speed and spontaneity. “As the name suggests, the main factor is

Read More »

Perth Now | 18 November 2023

Australian Associated Press journalist Derek Rose has shared LTR Pharma’s story following the launch of our IPO last week. Of the Company’s commercialisation plans, he wrote: “Because the drug is already approved in a different form, LTR should have an easier time bringing SPONTAN® to market than companies seeking approval

Read More »

Biotech Daily | 17 Nov 2023

LTR Pharma has been featured in Biotech Daily. The article discusses the potential for the Company to disrupt the Erectile Dysfunction (ED) market with its commercialisation plans for intra-nasal product, SPONTAN®. The article also showcases the expertise of the team at LTR Pharma, writing: “The company said its Mr Rodne

Read More »

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.